Venus Remedies Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

Pat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF Explain this filing

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.1%Reaction day

₹1160.00

prior close

₹1219.10

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.0%+5.1% vs market

Pharmaceuticals peers, median of 164sector+0.1%+5.0% vs sector

On the reaction day the stock moved 5.1 pts more than Nifty Microcap 250 and 5.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.1-0.0+5.1+0.1+5.0

Next day

+10.3-0.7+11.0-0.6+10.9

+15.9-1.8+17.6-1.3+17.2

+21.7-0.7+22.4-1.4+23.1

+27.7-0.5+28.2-1.6+29.3

+34.1+0.4+33.7-0.6+34.7

+41.9-1.6+43.5-2.3+44.2

15d

+48.5+4.6+43.9+0.0+48.5

+66.3+4.6+61.7+3.0+63.3

+35.6+6.1+29.4+4.3+31.3

+37.9+10.8+27.1+8.6+29.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Venus Remedies Limited reported strong audited financial results for FY2025-26 (standalone). Revenue from operations grew 19.3% to Rs. 768.73 crore from Rs. 644.47 crore. Net profit surged 89% to Rs. 99.31 crore from Rs. 52.55 crore. EBITDA expanded significantly to Rs. 155.37 crore from Rs. 90.77 crore, with margin improving from ~14% to ~20%. EPS (basic) stood at Rs. 74.29 versus Rs. 39.32. Consolidated net profit was Rs. 102.78 crore (up 127%). The Board recommended a final dividend of Rs. 10 per share (100%). Auditors issued an unmodified (clean) opinion. The company has a subsidiary in Germany (Venus Pharma GmbH) and step-down subsidiary in Hungary (Venus Pharma Kft).

Likely market impact

Strong financial performance with near doubling of profits and significant margin expansion indicates operational efficiency gains. The company appears fundamentally strong with cash flow from operations at Rs. 151.09 crore (standalone).